N-[2-(5-Chloro-2-hydroxy-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide | 1233186-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: N-[2-(5-Chloro-2-hydroxy-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide
• 英文别名: N-[2-(5-chloro-2-oxo-1H-pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl]-N-methylmethanesulfonamide
• CAS: 1233186-13-4
• 化学式: C₁₄H₁₃ClN₄O₃S
• 分子量: 352.801
• InChiKey: LHUGRRLXAATFPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  92.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-(5-Chloro-2-hydroxy-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide 生成 2-[4-[4-[[5-Chloro-7-[2-[methyl(methylsulfonyl)amino]phenyl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]piperidin-1-yl]acetamide
  参考文献：
  名称：

  Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases

  摘要：

  The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.049
• 作为产物：
  描述：

  N-(2-(5-chloro-2-(methylthio)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)methanesulfonamide 在 sodium tungstate 、 双氧水 、 sodium hydroxide 作用下， 生成 N-[2-(5-Chloro-2-hydroxy-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide
  参考文献：
  名称：

  Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases

  摘要：

  The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.049

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
  申请人：Breslin Henry J.

  公开号：US20120028919A1

  公开（公告）日：2012-02-02

  The present invention provides a compound of formula I or a salt form thereof, wherein Q 1 , Q 2 , Q 3 , and Q 4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了公式I或其盐形式的化合物，其中Q1、Q2、Q3和Q4的定义如本文所述。公式I的化合物具有ALK和/或JAK2抑制活性，可用于治疗增生性疾病。
• Pyrrolotriazines as ALK and JAK2 inhibitors
  申请人：Breslin Henry J.

  公开号：US08471005B2

  公开（公告）日：2013-06-25

  The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了公式I或其盐形式的化合物，其中Q1、Q2、Q3和Q4的定义如本文所述。公式I的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-<i>f</i>][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors
  作者：Eugen F. Mesaros、Tho V. Thieu、Gregory J. Wells、Craig A. Zificsak、Jason C. Wagner、Henry J. Breslin、Rabindranath Tripathy、James L. Diebold、Robert J. McHugh、Ashley T. Wohler、Matthew R. Quail、Weihua Wan、Lihui Lu、Zeqi Huang、Mark S. Albom、Thelma S. Angeles、Kevin J. Wells-Knecht、Lisa D. Aimone、Mangeng Cheng、Mark A. Ator、Gregory R. Ott、Bruce D. Dorsey

  DOI：10.1021/jm2010767

  日期：2012.1.12

  Chemical strategies to mitigate cytochrome P450-mediated bioactivation of novel 2,7-disubstituted pyrrolo[2,1-f][1,2,4]triazine ALK inhibitors are described along with synthesis and biological activity. Piperidine-derived analogues showing minimal microsomal reactive metabolite formation were discovered. Potent, selective, and metabolically stable ALK inhibitors from this class were identified, and an orally bioavailable compound (32) with antitumor efficacy in ALK-driven xenografts in mouse models was extensively characterized.
• US8471005B2
  申请人：——

  公开号：US8471005B2

  公开（公告）日：2013-06-25